FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 (NCT05614739)
FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.
Who can join: Review the eligibility criteria below.
Location: University of Arizona - Cancer Center — Tucson, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (82 Sites)
Showing the first 25 of 82 sites.
- University of Arizona - Cancer Center — Tucson, Arizona
- City of Hope — Duarte, California
- University of California, Los Angeles (UCLA) - Division of Hematology-Oncology — Los Angeles, California
- University of California - Irvine — Orange, California
- University of California (UC) Davis Comprehensive Cancer Center — Sacramento, California
- Stanford Medicine Cancer Center — Stanford, California
- Advent Health — Orlando, Florida
- Emory University Hospital — Atlanta, Georgia
- The University of Chicago Medical Center (UCMC) — Chicago, Illinois
- Indiana University (IU) Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- Mary Bird Perkins Cancer Center — Baton Rouge, Louisiana
- Ochsner Clinic Foundation — New Orleans, Louisiana
- Johns Hopkins Kimmel Cancer Center — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
- Washington University in St. Louis — St Louis, Missouri
- New York University (NYU) — New York, New York
- Weill Cornell Medicine — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Columbia University — New York, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
- University of Rochester - Wilmot Cancer Institute — Rochester, New York
- Montefiore Medical Center — The Bronx, New York
- University of North Carolina (UNC) - Chapel Hill — Chapel Hill, North Carolina
- University of Cincinnati Medical Center (UCMC) — Cincinnati, Ohio
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Urinary Bladder Neoplasms
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Loma Linda, California
- A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer — Tucson, Arizona
- A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) — Birmingham, Alabama
- Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) — Washington D.C., District of Columbia
- A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy — Tucson, Arizona
- A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) — Bakersfield, California
Explore by condition: All Urinary Bladder Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.